Carbamazepine versus resperidonein treatment of autistic symptoms
Other Title(s)
دراسة مقارنة بين الكاربامازيبين و الريسبريدون في علاج الأعراض الذاتوية
Joint Authors
Abd al-Baqi, Alawiyah Muhammad
Azzam, Hanan Muhammad Izz al-Din
al-Najjar, Ghadah Muhammad al-Said
Source
Issue
Vol. 20, Issue 76 (31 Jul. 2017), pp.13-18, 6 p.
Publisher
Ain Shams University Faculty of Graduate Studies for Childhood
Publication Date
2017-07-31
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background: Autism spectrum disorder (ASD), is a heterogeneous of neuro- developmental syndrome characterized by a wide range of impairments in social interactions, verbal and non- verbal communication and restricted and repetitive behaviors in the first three years of life.
There is no curative treatment for ASD, The early and correct diagnosis is important in successful intervention program.
Recently Risperidone is used to treat patients with ASD.
The children with ASD that show Electro- Encephalo* Graphic (EEG) changes are about 10.3% to 72.4% of patients.
The prevalence of epilepsy with Autistic children has been estimated at 7* 14%.
The management of seizures waves using Anti- Epileptic Drugs such as Carbamazepine in children and adolescents with ASD may cause functional improvement and reduction of autistic symptoms.
Although pharmacological treatment is beneficial in decreasing symptoms in ASD, Behavior Modification must associate these pharmacological agents.
Objectives: To assess the effect of Risperidone, Carbamazepine, and Behavioral Modification in decreasing severity of the symptoms of ASD.
Patients and Methods: Sixty patients were diagnosed as having ASD according to Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM- V), then the sample is divided into three groups.
The first group will be given Risperidone and Behavior Modification.
The second group will be given Carbamazepine and Behavior Modification.
The third group will be given Behavior Modification only.
The duration of the study was six months.
Evaluation of symptoms of ASD was done before the study and after the study.
Statistical analysis was done.
Results: Clinical and Statistical improvement occurred between before the study and after the study.
On the other hand, there are no statistical significant results from comparing the three groups after the study.
Conclusion: Risperidone and Carbamazepine are effective and tolerable agents in the course of treatment of ASD.
Behavior Modification is non- pharmacological effective treatment of ASD.
American Psychological Association (APA)
Abd al-Baqi, Alawiyah Muhammad& Azzam, Hanan Muhammad Izz al-Din& al-Najjar, Ghadah Muhammad al-Said. 2017. Carbamazepine versus resperidonein treatment of autistic symptoms. Journal of Childhood Studies،Vol. 20, no. 76, pp.13-18.
https://search.emarefa.net/detail/BIM-860154
Modern Language Association (MLA)
Abd al-Baqi, Alawiyah Muhammad…[et al.]. Carbamazepine versus resperidonein treatment of autistic symptoms. Journal of Childhood Studies Vol. 20, no. 76 (Jul. 2017), pp.13-18.
https://search.emarefa.net/detail/BIM-860154
American Medical Association (AMA)
Abd al-Baqi, Alawiyah Muhammad& Azzam, Hanan Muhammad Izz al-Din& al-Najjar, Ghadah Muhammad al-Said. Carbamazepine versus resperidonein treatment of autistic symptoms. Journal of Childhood Studies. 2017. Vol. 20, no. 76, pp.13-18.
https://search.emarefa.net/detail/BIM-860154
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 17-18
Record ID
BIM-860154